Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 4, 2004

View Archived Issues

Ondansetron found to improve fatigue and depression in chronic hepatitis C

Enrollment opens in phase III trial of MDX-010 for metastatic melanoma

Promising clinical results reported for NicVAX in smoking cessation

Phase II results on the efficacy of Deltavasc in peripheral artery disease

Good safety profile of sargramostim in moderate to severe Crohn's disease

Novel antiinflammatory chalcones patented by Taiwan university researchers

Another series of anti-HIV chemokine CCR5 antagonists presented by Takeda

New anticytomegalovirus agents prepared and tested at Bayer

Cellular Genomics presents new Hsp90 modulators

Novel vanilloid VR1 modulators covered by Amgen patent

New immunomodulators claimed for use in viral infections and cancer

BMS scientists describe new p38 kinase inhibitors

ISTA and Allergan sign new Vitrase agreement

Metvix approved in eight more European countries

Menarini launches frovatriptan in Italy

Favorable review for Neurologix's protocol for epilepsy gene therapy study

BioInvent and ThromboGenics to develop treatments for vascular indications

BTG enters into agreements in field of sleep apnea

Phase I/II study for KAI-9803 in reperfusion injury

AZD-2171 useful in combination with other antitumor agents

Daily administration of A6 well tolerated in gynecological cancer patients

Selenophene derivative induces apoptosis in renal cancer cells

Daily oral CP-724714 well tolerated in first clinical study

Oxis International licenses BXT-51072 and compounds to HaptoGuard

Preliminary clinical results reported for chimeric anti-alpha5beta1 MAb

Therapeutic benefits of Alequel found in patients with moderate to severe CD

Metformin and insulin reported to induce metabolic effects in patients with burns

Studies show biological activity and tolerability of AZD-3409

Two-year follow-up data for TAXUS IV trial

Effects of bovine lactoferrin supplementation in the eradication of H. pylori infection

Alizyme cleared for phase IIb study of ATL-962 for obesity

Approval sought for proof-of-concept study for ATL-1101 in psoriasis

Triple angiokinase inhibitor, BIBF-1120, shows promise for clinical development

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...